{"id":8776,"date":"2026-09-22T22:21:50","date_gmt":"2026-09-23T02:21:50","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/societe\/conseil-dadministration\/"},"modified":"2026-10-29T17:12:48","modified_gmt":"2026-10-29T16:12:48","slug":"conseil-dadministration","status":"publish","type":"page","link":"https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/","title":{"rendered":"Conseil d&rsquo;administration"},"content":{"rendered":"\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-mqvfvik7-850ed2833211035f10ee637fa51c32ec\">\n.avia-section.av-mqvfvik7-850ed2833211035f10ee637fa51c32ec{\nbackground-color:#0e1539;\nbackground-image:unset;\n}\n<\/style>\n<div id='av_section_1'  class='avia-section av-mqvfvik7-850ed2833211035f10ee637fa51c32ec main_color avia-section-huge avia-no-border-styling  avia-builder-el-0  el_before_av_submenu  avia-builder-el-first  invalid-custom-class-found page-banner unset-row medium-padding-bottom avia-bg-style-scroll container_wrap sidebar_right'  ><div class='container av-section-cont-open' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-8776'><div class='entry-content-wrapper clearfix'>\n<div  class='flex_column av-gqe85-fccb89636dbb2dfeb2d251de1370f59a av_one_full  avia-builder-el-1  avia-builder-el-no-sibling  first flex_column_div av-animated-generic fade-in  '     ><section  class='av_textblock_section av-avwal-9aae7976204d416cba9af293fed5851f '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock page-banner-content'  itemprop=\"text\" ><h1>Leadership<\/h1>\n<\/div><\/section><\/div><\/div><\/div><\/main><!-- close content main element --><\/div><\/div><div id='sub_menu1'  class='av-submenu-container av-ip6w4-e105fd9bbd6c99902fd1ae980b773493 main_color av-switch-990  avia-builder-el-3  el_after_av_section  el_before_av_section  submenu-not-first container_wrap sidebar_right' style='z-index:301' ><div class='container av-menu-mobile-active av-submenu-pos-center'><a href=\"#\" class=\"mobile_menu_toggle\"><span class='avia-svg-icon avia-font-svg_entypo-fontello' data-av_svg_icon='list' data-av_iconset='svg_entypo-fontello'><svg version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"22\" height=\"32\" viewBox=\"0 0 22 32\" preserveAspectRatio=\"xMidYMid meet\" aria-labelledby='av-svg-title-1' aria-describedby='av-svg-desc-1' role=\"graphics-symbol\" aria-hidden=\"true\">\n<title id='av-svg-title-1'>List<\/title>\n<desc id='av-svg-desc-1'>List<\/desc>\n<path d=\"M3.2 20.8q0.64 0 1.12 0.48t0.48 1.12-0.48 1.12-1.12 0.48h-1.6q-0.64 0-1.12-0.48t-0.48-1.12 0.448-1.12 1.152-0.48h1.6zM3.2 14.4q0.64 0 1.12 0.48t0.48 1.12-0.48 1.12-1.12 0.48h-1.6q-0.64 0-1.12-0.48t-0.48-1.12 0.448-1.12 1.152-0.48h1.6zM3.2 8q0.64 0 1.12 0.48t0.48 1.12-0.48 1.12-1.12 0.48h-1.6q-0.64 0-1.12-0.48t-0.48-1.12 0.448-1.12 1.152-0.48h1.6zM9.6 11.2q-0.64 0-1.12-0.48t-0.48-1.12 0.48-1.12 1.12-0.48h11.2q0.704 0 1.152 0.48t0.448 1.12-0.48 1.12-1.12 0.48h-11.2zM20.8 14.4q0.704 0 1.152 0.48t0.448 1.12-0.48 1.12-1.12 0.48h-11.2q-0.64 0-1.12-0.48t-0.48-1.12 0.48-1.12 1.12-0.48h11.2zM20.8 20.8q0.704 0 1.152 0.48t0.448 1.12-0.48 1.12-1.12 0.48h-11.2q-0.64 0-1.12-0.48t-0.48-1.12 0.48-1.12 1.12-0.48h11.2z\"><\/path>\n<\/svg><\/span><span class=\"av-current-placeholder\">Menu<\/span><\/a><ul id=\"menu-team-menu\" class=\"av-subnav-menu\" role=\"menu\"><li role=\"menuitem\" id=\"menu-item-425\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-top-level menu-item-top-level-1\"><a href=\"https:\/\/www.gensight-biologics.com\/company\/leadership\/\" itemprop=\"url\" tabindex=\"0\"><span class=\"avia-bullet\"><\/span><span class=\"avia-menu-text\">Direction<\/span><span class=\"avia-menu-fx\"><span class=\"avia-arrow-wrap\"><span class=\"avia-arrow\"><\/span><\/span><\/span><\/a><\/li>\n<li role=\"menuitem\" id=\"menu-item-476\" class=\"menu-item menu-item-type-post_type menu-item-object-page menu-item-top-level menu-item-top-level-2\"><a href=\"https:\/\/www.gensight-biologics.com\/company\/board-of-directors\/\" itemprop=\"url\" tabindex=\"0\"><span class=\"avia-bullet\"><\/span><span class=\"avia-menu-text\">Conseil d&rsquo;administration<\/span><span class=\"avia-menu-fx\"><span class=\"avia-arrow-wrap\"><span class=\"avia-arrow\"><\/span><\/span><\/span><\/a><\/li>\n<\/ul><\/div><\/div><\/p>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-mqze5ot2-b4a68eee4e1f86ee5dbe970d644b8127\">\n.avia-section.av-mqze5ot2-b4a68eee4e1f86ee5dbe970d644b8127{\nbackground-color:#0e1539;\nbackground-image:url(https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-834.png);\nbackground-repeat:no-repeat;\nbackground-position:0% 50%;\nbackground-attachment:scroll;\n}\n<\/style>\n<div id='av_section_2'  class='avia-section av-mqze5ot2-b4a68eee4e1f86ee5dbe970d644b8127 main_color avia-section-large avia-no-border-styling  avia-builder-el-4  el_after_av_submenu  avia-builder-el-last  unset-row flex-row invalid-custom-class-found background-radial-top-right-offset avia-full-contain avia-bg-style-scroll container_wrap sidebar_right'  data-section-bg-repeat='contain'><div class='container av-section-cont-open' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-8776'><div class='entry-content-wrapper clearfix'>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-mqzdkh37-35f360b81c75cf69b2ea2accc0119c31\">\n.avia-image-container.av-mqzdkh37-35f360b81c75cf69b2ea2accc0119c31 img.avia_image{\nbox-shadow:none;\n}\n.avia-image-container.av-mqzdkh37-35f360b81c75cf69b2ea2accc0119c31 .av-image-caption-overlay-center{\ncolor:#ffffff;\n}\n<\/style>\n<div  class='avia-image-container av-mqzdkh37-35f360b81c75cf69b2ea2accc0119c31 av-styling- av-hover-fade avia-align-center  avia-builder-el-5  el_before_av_image  avia-builder-el-first  offset-top top-right-dots-img animated-dots flip-dots'   itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\" ><div class=\"avia-image-container-inner\"><div class=\"avia-image-overlay-wrap\"><img decoding=\"async\" fetchpriority=\"high\" class='wp-image-8016 avia-img-lazy-loading-not-8016 avia_image fade-basic' src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/ani-dots-1.svg\" alt='' title='ani-dots-1'  height=\"500\" width=\"90\"  itemprop=\"thumbnailUrl\"  \/><img decoding=\"async\" class='wp-image-8019 avia-img-lazy-loading-not-8019 avia_image fade-overlay' src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/ani-dots-2.svg\" alt='' title='ani-dots-1'  height=\"500\" width=\"90\"  itemprop=\"thumbnailUrl\"  \/><\/div><\/div><\/div>\n\n<style type=\"text\/css\" data-created_by=\"avia_inline_auto\" id=\"style-css-av-mr0wsza5-db97260da3fecc0a775e1952ea2bb9c9\">\n.avia-image-container.av-mr0wsza5-db97260da3fecc0a775e1952ea2bb9c9 img.avia_image{\nbox-shadow:none;\n}\n.avia-image-container.av-mr0wsza5-db97260da3fecc0a775e1952ea2bb9c9 .av-image-caption-overlay-center{\ncolor:#ffffff;\n}\n<\/style>\n<div  class='avia-image-container av-mr0wsza5-db97260da3fecc0a775e1952ea2bb9c9 av-styling- av-hover-fade avia-align-center  avia-builder-el-6  el_after_av_image  el_before_av_one_full  bottom-left-dots-img animated-dots'   itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\" ><div class=\"avia-image-container-inner\"><div class=\"avia-image-overlay-wrap\"><img decoding=\"async\" class='wp-image-8016 avia-img-lazy-loading-not-8016 avia_image fade-basic' src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/ani-dots-1.svg\" alt='' title='ani-dots-1'  height=\"500\" width=\"90\"  itemprop=\"thumbnailUrl\"  \/><img decoding=\"async\" class='wp-image-8019 avia-img-lazy-loading-not-8019 avia_image fade-overlay' src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/ani-dots-2.svg\" alt='' title='ani-dots-1'  height=\"500\" width=\"90\"  itemprop=\"thumbnailUrl\"  \/><\/div><\/div><\/div>\n<div  class='flex_column av-9u3yd-40b1f7f46f4e9ef1df4daef20c03771a av_one_full  avia-builder-el-7  el_after_av_image  avia-builder-el-last  first flex_column_div av-animated-generic bottom-to-top  '     ><section  class='av_textblock_section av-mqzdhg6h-259f8e76dd0e1f1f59a11e6e3d7a9b6b '   itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/CreativeWork\" ><div class='avia_textblock'  itemprop=\"text\" ><div class=\"team-holder\"><div class=\"team-member staff-team\"><div class=\"team-member-inner\"><div class=\"image-and-links\"><div class=\"team-member-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841.png\" class=\"wp-image-8544 avia-img-lazy-loading-8544 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"read-bio-and-social\"><button class=\"view-bio open-popup avia-button\" popup-target=\"#8543\">Biographie<\/button><div class=\"social-links\"><\/div><\/div><\/div><div class=\"team-member-content\"><div class=\"textblock\"><h4 class=\"open-popup\" popup-target=\"#8543\">Michael Wyzga<\/h4><p class=\"job-title\">Pr\u00e9sident<\/p><\/div><\/div><\/div><div id=\"8543\" class=\"popup-content\"><div class=\"popup-bg\"><\/div><div class=\"popup-inner\"><div class=\"popup-aligner\"><div class=\"popup-dots\"><img decoding=\"async\" class=\"default\" src=\"\/wp-content\/uploads\/2026\/06\/Group-5895-3.png\" alt=\"decorative dots\" \/><img decoding=\"async\" class=\"hover\" src=\"\/wp-content\/uploads\/2026\/09\/Group-5895-1.png\" alt=\"decorative dots\" \/><\/div><div class=\"popup-close\"><span class=\"popup-close-inner\"><\/span><\/div><div class=\"popup-inner-content\"><div class=\"popup-left\"><div class=\"popup-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841.png\" class=\"wp-image-8544 avia-img-lazy-loading-8544 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-841-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"social-links\"><\/div><\/div><div class=\"popup-right\"><h2>Michael Wyzga<\/h2><h4>Pr\u00e9sident<\/h4>\n<p class=\"wp-block-paragraph\">Michael Wyzga est administrateur depuis octobre 2013 et Pr\u00e9sident du Conseil d&rsquo;administration depuis mars 2016. Il est actuellement Pr\u00e9sident de MSW Consulting, Inc., soci\u00e9t\u00e9 de conseil strat\u00e9gique aupr\u00e8s des industries pharmaceutique et biotechnologique.<\/p>\n\n<p class=\"wp-block-paragraph\">M. Wyzga a occup\u00e9 plusieurs postes de direction chez Genzyme Corporation, soci\u00e9t\u00e9 biopharmaceutique rachet\u00e9e par Sanofi en 2011, notamment celui de Vice-Pr\u00e9sident ex\u00e9cutif Finances et Directeur financier. De 2011 \u00e0 2013, il a \u00e9t\u00e9 Pr\u00e9sident-Directeur g\u00e9n\u00e9ral de Radius Health, Inc., dont il \u00e9tait \u00e9galement administrateur.<\/p>\n\n<p class=\"wp-block-paragraph\">M. Wyzga poss\u00e8de une solide exp\u00e9rience des conseils d&rsquo;administration de soci\u00e9t\u00e9s des sciences de la vie. Il a \u00e9t\u00e9 administrateur et pr\u00e9sident du comit\u00e9 d&rsquo;audit d&rsquo;OncoMed Pharmaceuticals, Inc., de 2013 jusqu&rsquo;\u00e0 sa fusion avec Mereo BioPharma Group plc en 2019. Il a \u00e9galement \u00e9t\u00e9 administrateur d&rsquo;Akebia Therapeutics, Inc., o\u00f9 il pr\u00e9sidait le comit\u00e9 d&rsquo;audit et si\u00e9geait au comit\u00e9 de r\u00e9mun\u00e9ration, et administrateur d&rsquo;Exact Sciences Corporation, o\u00f9 il \u00e9tait membre des comit\u00e9s d&rsquo;audit et de r\u00e9mun\u00e9ration. Il a par le pass\u00e9 si\u00e9g\u00e9 aux conseils d&rsquo;Idenix Pharmaceuticals, Inc., d&rsquo;Altus Pharmaceuticals, Inc. et de Prosensa Holding B.V. Outre GenSight Biologics, il est aujourd&rsquo;hui administrateur de X4 Pharmaceuticals, de Mereo BioPharma Group plc et d&rsquo;Invivyd, Inc.<\/p>\n\n<p class=\"wp-block-paragraph\">Michael Wyzga est titulaire d&rsquo;un MBA de Providence College et d&rsquo;une licence en sciences (B.S.) de l&rsquo;Universit\u00e9 Suffolk.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><div class=\"team-member staff-team\"><div class=\"team-member-inner\"><div class=\"image-and-links\"><div class=\"team-member-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez.png\" class=\"wp-image-8338 avia-img-lazy-loading-8338 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"read-bio-and-social\"><button class=\"view-bio open-popup avia-button\" popup-target=\"#8545\">Biographie<\/button><div class=\"social-links\"><\/div><\/div><\/div><div class=\"team-member-content\"><div class=\"textblock\"><h4 class=\"open-popup\" popup-target=\"#8545\">Laurence Rodriguez<\/h4><p class=\"job-title\">Administratrice<\/p><\/div><\/div><\/div><div id=\"8545\" class=\"popup-content\"><div class=\"popup-bg\"><\/div><div class=\"popup-inner\"><div class=\"popup-aligner\"><div class=\"popup-dots\"><img decoding=\"async\" class=\"default\" src=\"\/wp-content\/uploads\/2026\/06\/Group-5895-3.png\" alt=\"decorative dots\" \/><img decoding=\"async\" class=\"hover\" src=\"\/wp-content\/uploads\/2026\/09\/Group-5895-1.png\" alt=\"decorative dots\" \/><\/div><div class=\"popup-close\"><span class=\"popup-close-inner\"><\/span><\/div><div class=\"popup-inner-content\"><div class=\"popup-left\"><div class=\"popup-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez.png\" class=\"wp-image-8338 avia-img-lazy-loading-8338 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/07\/laurence-rodriguez-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"social-links\"><\/div><\/div><div class=\"popup-right\"><h2>Laurence Rodriguez<\/h2><h4>Administratrice<\/h4>\n<p class=\"wp-block-paragraph\">Laurence Rodriguez poss\u00e8de plus de 30 ans d&rsquo;exp\u00e9rience dans le secteur des sciences de la vie, dont 13 ans dans les maladies rares chez Sanofi. Elle a contribu\u00e9 \u00e0 l&rsquo;implantation, \u00e0 la croissance et au succ\u00e8s de Genzyme en France, devenu un leader des maladies rares, jusqu&rsquo;\u00e0 son rachat par Sanofi en 2011. Apr\u00e8s cette acquisition, elle a occup\u00e9 plusieurs fonctions op\u00e9rationnelles et strat\u00e9giques si\u00e9geant au comit\u00e9 ex\u00e9cutif. Directrice de l&rsquo;entit\u00e9 \u00ab Maladies rares et maladies h\u00e9matologiques rares \u00bb de Sanofi, elle a supervis\u00e9 le lancement r\u00e9ussi de plusieurs traitements d\u00e9velopp\u00e9s en interne ou issus d&rsquo;acquisitions.<\/p>\n\n<p class=\"wp-block-paragraph\">Elle a rejoint GenSight Biologics en mai 2021 comme Directrice des Op\u00e9rations pour la France et le Benelux. Elle y a coordonn\u00e9 le programme d&rsquo;acc\u00e8s pr\u00e9coce, pr\u00e9par\u00e9 la commercialisation de LUMEVOQ\u00ae et nou\u00e9 des relations de confiance durables avec les principales parties prenantes du march\u00e9 fran\u00e7ais. <\/p>\n\n<p class=\"wp-block-paragraph\">En d\u00e9cembre 2023, le Conseil d&rsquo;administration de GenSight Biologics l&rsquo;a nomm\u00e9e Directrice G\u00e9n\u00e9rale pour conduire la nouvelle strat\u00e9gie de la Soci\u00e9t\u00e9. En 2025, elle a \u00e9t\u00e9 \u00e9lue au Coll\u00e8ge Biotech du conseil d&rsquo;administration de France Biotech, l&rsquo;association professionnelle des entreprises de biotechnologie en France, puis en 2026 au conseil d&rsquo;administration du LEEM, l&rsquo;organisation qui r\u00e9unit les entreprises du m\u00e9dicament pr\u00e9sentes en France.<\/p>\n\n<p class=\"wp-block-paragraph\">Laurence Rodriguez est titulaire d&rsquo;un master en management et politiques de sant\u00e9 de Sciences Po Paris et d&rsquo;une licence en sciences (B.Sc.) de l&rsquo;Universit\u00e9 de Paris. Elle a compl\u00e9t\u00e9 son parcours par un programme de leadership organisationnel \u00e0 la Harvard Business School.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><div class=\"team-member staff-team\"><div class=\"team-member-inner\"><div class=\"image-and-links\"><div class=\"team-member-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre.webp\" class=\"wp-image-8637 avia-img-lazy-loading-8637 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre.webp 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre-300x300.webp 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre-80x80.webp 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre-36x36.webp 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre-180x180.webp 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"read-bio-and-social\"><button class=\"view-bio open-popup avia-button\" popup-target=\"#8546\">Biographie<\/button><div class=\"social-links\"><\/div><\/div><\/div><div class=\"team-member-content\"><div class=\"textblock\"><h4 class=\"open-popup\" popup-target=\"#8546\">Maritza McIntyre, Ph.D.<\/h4><p class=\"job-title\">Administratrice ind\u00e9pendante<\/p><\/div><\/div><\/div><div id=\"8546\" class=\"popup-content\"><div class=\"popup-bg\"><\/div><div class=\"popup-inner\"><div class=\"popup-aligner\"><div class=\"popup-dots\"><img decoding=\"async\" class=\"default\" src=\"\/wp-content\/uploads\/2026\/06\/Group-5895-3.png\" alt=\"decorative dots\" \/><img decoding=\"async\" class=\"hover\" src=\"\/wp-content\/uploads\/2026\/09\/Group-5895-1.png\" alt=\"decorative dots\" \/><\/div><div class=\"popup-close\"><span class=\"popup-close-inner\"><\/span><\/div><div class=\"popup-inner-content\"><div class=\"popup-left\"><div class=\"popup-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre.webp\" class=\"wp-image-8637 avia-img-lazy-loading-8637 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre.webp 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre-300x300.webp 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre-80x80.webp 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre-36x36.webp 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/BOD_maritz-mclntyre-180x180.webp 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"social-links\"><\/div><\/div><div class=\"popup-right\"><h2>Maritza McIntyre, Ph.D.<\/h2><h4>Administratrice ind\u00e9pendante<\/h4>\n<p class=\"wp-block-paragraph\">Maritza McIntyre est administratrice de GenSight Biologics depuis 2019. Elle est Pr\u00e9sidente d&rsquo;Advanced Therapies Partners, LLC, o\u00f9 elle conseille des soci\u00e9t\u00e9s de biotechnologie, des universitaires et des fonds de capital-risque en mati\u00e8re de strat\u00e9gie r\u00e9glementaire et de d\u00e9veloppement de produits. <\/p>\n\n<p class=\"wp-block-paragraph\">Elle poss\u00e8de 20 ans d&rsquo;exp\u00e9rience dans le d\u00e9veloppement, l&rsquo;\u00e9valuation et la r\u00e9glementation de produits biologiques et de petites mol\u00e9cules, acquise au sein de jeunes soci\u00e9t\u00e9s de biotechnologie, \u00e0 la FDA et comme consultante. \u00c0 travers sa participation \u00e0 des associations du secteur, dont l&rsquo;ASGCT et le Standards Coordinating Body, elle continue de contribuer \u00e0 l&rsquo;\u00e9laboration de la r\u00e9glementation applicable \u00e0 la th\u00e9rapie g\u00e9nique. <\/p>\n\n<p class=\"wp-block-paragraph\">Mme McIntyre a \u00e9t\u00e9 examinatrice de produits, puis chef de service (Branch Chief) au sein de la division des th\u00e9rapies cellulaires et g\u00e9niques de la FDA\/CBER, o\u00f9 elle a activement particip\u00e9 \u00e0 l&rsquo;\u00e9laboration des politiques et aux \u00e9changes avec les parties prenantes. Elle a ensuite occup\u00e9 des postes de direction en affaires r\u00e9glementaires et d\u00e9veloppement de produits chez Bavarian Nordic, REGENXBIO, NanoCor Therapeutics et Bamboo Therapeutics. Elle a \u00e9galement contribu\u00e9 \u00e0 la pr\u00e9paration de certaines des premi\u00e8res demandes de licence de produit biologique (BLA) et d&rsquo;autorisation de mise sur le march\u00e9 (AMM) d\u00e9pos\u00e9es pour des produits de th\u00e9rapie g\u00e9nique aupr\u00e8s de la FDA et de l&rsquo;EMA.  <\/p>\n\n<p class=\"wp-block-paragraph\">Maritza McIntyre est titulaire d&rsquo;un doctorat en virologie de l&rsquo;Universit\u00e9 de Chicago et dipl\u00f4m\u00e9e en biologie (mention magna cum laude) de l&rsquo;Universit\u00e9 Wayne State.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><div class=\"team-member staff-team\"><div class=\"team-member-inner\"><div class=\"image-and-links\"><div class=\"team-member-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9.png\" class=\"wp-image-8549 avia-img-lazy-loading-8549 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"read-bio-and-social\"><button class=\"view-bio open-popup avia-button\" popup-target=\"#8548\">Biographie<\/button><div class=\"social-links\"><\/div><\/div><\/div><div class=\"team-member-content\"><div class=\"textblock\"><h4 class=\"open-popup\" popup-target=\"#8548\">C\u00e9dric Moreau<\/h4><p class=\"job-title\">Repr\u00e9sentant de Sofinnova Partners<\/p><\/div><\/div><\/div><div id=\"8548\" class=\"popup-content\"><div class=\"popup-bg\"><\/div><div class=\"popup-inner\"><div class=\"popup-aligner\"><div class=\"popup-dots\"><img decoding=\"async\" class=\"default\" src=\"\/wp-content\/uploads\/2026\/06\/Group-5895-3.png\" alt=\"decorative dots\" \/><img decoding=\"async\" class=\"hover\" src=\"\/wp-content\/uploads\/2026\/09\/Group-5895-1.png\" alt=\"decorative dots\" \/><\/div><div class=\"popup-close\"><span class=\"popup-close-inner\"><\/span><\/div><div class=\"popup-inner-content\"><div class=\"popup-left\"><div class=\"popup-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9.png\" class=\"wp-image-8549 avia-img-lazy-loading-8549 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-9-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"social-links\"><\/div><\/div><div class=\"popup-right\"><h2>C\u00e9dric Moreau<\/h2><h4>Repr\u00e9sentant de Sofinnova Partners<\/h4>\n<p class=\"wp-block-paragraph\">C\u00e9dric Moreau est administrateur de GenSight Biologics, repr\u00e9sentant de Sofinnova Partners, depuis juin 2019. Il apporte des d\u00e9cennies d&rsquo;exp\u00e9rience dans la banque d&rsquo;investissement d\u00e9di\u00e9e aux sciences de la vie. Au total, il a pilot\u00e9 des op\u00e9rations (introductions en Bourse, placements secondaires et PIPE) sur des soci\u00e9t\u00e9s de sant\u00e9 europ\u00e9ennes, pour une valeur cumul\u00e9e d&rsquo;environ 2 milliards d&rsquo;euros. <\/p>\n\n<p class=\"wp-block-paragraph\">M. Moreau a rejoint Sofinnova Partners en juin 2018, apportant \u00e0 l&rsquo;\u00e9quipe Sofinnova Crossover son expertise transactionnelle dans l&rsquo;industrie biopharmaceutique ainsi qu&rsquo;un vaste r\u00e9seau de leaders d&rsquo;opinion (KOL), de banquiers et d&rsquo;avocats. Il venait d&rsquo;Oddo BHF, o\u00f9 il \u00e9tait Managing Director et responsable du secteur Sant\u00e9 au sein du d\u00e9partement Corporate Finance. En 2017, Oddo BHF s&rsquo;est class\u00e9 en t\u00eate des palmar\u00e8s europ\u00e9ens des op\u00e9rations de march\u00e9 actions dans la biotechnologie. Auparavant, il avait \u00e9t\u00e9 directeur chez Bryan Garnier &amp; Co., o\u00f9 il a men\u00e9 plusieurs op\u00e9rations transfrontali\u00e8res d&rsquo;envergure.    <\/p>\n\n<p class=\"wp-block-paragraph\">Avant sa carri\u00e8re dans le financement d&rsquo;entreprise, M. Moreau a pass\u00e9 10 ans comme analyste actions du secteur de la sant\u00e9, plusieurs fois class\u00e9 en t\u00eate du palmar\u00e8s EXTEL, \u00e0 titre individuel comme en \u00e9quipe, chez Natixis et Fortis. Il y assurait le suivi de soci\u00e9t\u00e9s cot\u00e9es de la biotechnologie et de la pharmacie.  <\/p>\n\n<p class=\"wp-block-paragraph\">C\u00e9dric Moreau est titulaire d&rsquo;un master en \u00e9conomie et d&rsquo;un dipl\u00f4me de troisi\u00e8me cycle en finance et fiscalit\u00e9 de la Sorbonne, ainsi que d&rsquo;un dipl\u00f4me de la Soci\u00e9t\u00e9 Fran\u00e7aise des Analystes Financiers (SFAF).<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><div class=\"team-member staff-team\"><div class=\"team-member-inner\"><div class=\"image-and-links\"><div class=\"team-member-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10.png\" class=\"wp-image-8551 avia-img-lazy-loading-8551 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"read-bio-and-social\"><button class=\"view-bio open-popup avia-button\" popup-target=\"#8550\">Biographie<\/button><div class=\"social-links\"><\/div><\/div><\/div><div class=\"team-member-content\"><div class=\"textblock\"><h4 class=\"open-popup\" popup-target=\"#8550\">Simone Seiter, M.D., Ph.D.<\/h4><p class=\"job-title\">Administratrice ind\u00e9pendante<\/p><\/div><\/div><\/div><div id=\"8550\" class=\"popup-content\"><div class=\"popup-bg\"><\/div><div class=\"popup-inner\"><div class=\"popup-aligner\"><div class=\"popup-dots\"><img decoding=\"async\" class=\"default\" src=\"\/wp-content\/uploads\/2026\/06\/Group-5895-3.png\" alt=\"decorative dots\" \/><img decoding=\"async\" class=\"hover\" src=\"\/wp-content\/uploads\/2026\/09\/Group-5895-1.png\" alt=\"decorative dots\" \/><\/div><div class=\"popup-close\"><span class=\"popup-close-inner\"><\/span><\/div><div class=\"popup-inner-content\"><div class=\"popup-left\"><div class=\"popup-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10.png\" class=\"wp-image-8551 avia-img-lazy-loading-8551 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-10-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"social-links\"><\/div><\/div><div class=\"popup-right\"><h2>Simone Seiter, M.D., Ph.D.<\/h2><h4>Administratrice ind\u00e9pendante<\/h4>\n<p class=\"wp-block-paragraph\">Le Dr Simone Seiter est Senior Partner chez Simon-Kucher &amp; Partners, cabinet de conseil de premier plan en strat\u00e9gie commerciale pour les sciences de la vie, depuis 2020. La m\u00eame ann\u00e9e, elle a cofond\u00e9 Priothera, une biotech en oncologie, en phase pr\u00e9-commerciale et bas\u00e9e en Irlande, dont elle pr\u00e9side aujourd&rsquo;hui le comit\u00e9 consultatif clinique et commercial. <\/p>\n\n<p class=\"wp-block-paragraph\">Avant Simon-Kucher &amp; Partners, le Dr Seiter a \u00e9t\u00e9 Vice-Pr\u00e9sidente d&rsquo;IQVIA, \u00e0 Francfort (Allemagne), de 2006 \u00e0 2019. Elle avait auparavant \u00e9t\u00e9 consultante pendant six ans chez Capgemini.<\/p>\n\n<p class=\"wp-block-paragraph\">Le Dr Seiter est titulaire d&rsquo;un doctorat en m\u00e9decine et en sciences de l&rsquo;Universit\u00e9 de Heidelberg et d&rsquo;un MBA de l&rsquo;Universit\u00e9 des sciences appliqu\u00e9es de Neu-Ulm, en Allemagne. Elle a effectu\u00e9 un post-doctorat de deux ans aux National Institutes of Health (\u00c9tats-Unis) et a exerc\u00e9 comme dermatologue \u00e0 l&rsquo;Universit\u00e9 de Heidelberg et \u00e0 Homburg, en Allemagne.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><div class=\"team-member staff-team\"><div class=\"team-member-inner\"><div class=\"image-and-links\"><div class=\"team-member-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11.png\" class=\"wp-image-8553 avia-img-lazy-loading-8553 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"read-bio-and-social\"><button class=\"view-bio open-popup avia-button\" popup-target=\"#8552\">Biographie<\/button><div class=\"social-links\"><\/div><\/div><\/div><div class=\"team-member-content\"><div class=\"textblock\"><h4 class=\"open-popup\" popup-target=\"#8552\">Fran\u00e7oise de Craecker<\/h4><p class=\"job-title\">Administratrice ind\u00e9pendante<\/p><\/div><\/div><\/div><div id=\"8552\" class=\"popup-content\"><div class=\"popup-bg\"><\/div><div class=\"popup-inner\"><div class=\"popup-aligner\"><div class=\"popup-dots\"><img decoding=\"async\" class=\"default\" src=\"\/wp-content\/uploads\/2026\/06\/Group-5895-3.png\" alt=\"decorative dots\" \/><img decoding=\"async\" class=\"hover\" src=\"\/wp-content\/uploads\/2026\/09\/Group-5895-1.png\" alt=\"decorative dots\" \/><\/div><div class=\"popup-close\"><span class=\"popup-close-inner\"><\/span><\/div><div class=\"popup-inner-content\"><div class=\"popup-left\"><div class=\"popup-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11.png\" class=\"wp-image-8553 avia-img-lazy-loading-8553 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-11-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"social-links\"><\/div><\/div><div class=\"popup-right\"><h2>Fran\u00e7oise de Craecker<\/h2><h4>Administratrice ind\u00e9pendante<\/h4>\n<p class=\"wp-block-paragraph\">Fran\u00e7oise de Craecker a rejoint le Conseil d&rsquo;administration comme administratrice ind\u00e9pendante en 2021. Mme de Craecker a dirig\u00e9 la r\u00e9gion EMEA (Europe, Moyen-Orient et Afrique) chez AveXis, soci\u00e9t\u00e9 rachet\u00e9e par Novartis en 2018. Elle y a constitu\u00e9 de toutes pi\u00e8ces l&rsquo;\u00e9quipe pluridisciplinaire charg\u00e9e du lancement de ZOLGENSMA\u00ae pour la r\u00e9gion EMEA, premi\u00e8re th\u00e9rapie g\u00e9nique en une seule injection contre l&rsquo;amyotrophie spinale. Elle a ouvert la voie \u00e0 l&rsquo;homologation, \u00e0 la distribution, \u00e0 l&rsquo;acc\u00e8s au march\u00e9 et \u00e0 la commercialisation du produit, en travaillant avec les autorit\u00e9s sur des m\u00e9canismes de financement innovants et l&rsquo;acc\u00e8s pr\u00e9coce. Elle a \u00e9galement implant\u00e9 le produit sur les principaux march\u00e9s europ\u00e9ens et b\u00e2ti un r\u00e9seau de distributeurs au Moyen-Orient et dans d&rsquo;autres pays europ\u00e9ens.<\/p>\n\n<p class=\"wp-block-paragraph\">Avant AveXis, Mme de Craecker a dirig\u00e9 les op\u00e9rations EMEA de Raptor Pharmaceuticals (ensuite rachet\u00e9e par Horizon puis Chiesi) \u00e0 la phase critique du passage de la R&amp;D \u00e0 la commercialisation de son produit phare dans la cystinose, suivi du lancement d&rsquo;un produit acquis dans la mucoviscidose. Auparavant, elle a pass\u00e9 14 ans chez Shire Human Genetics, o\u00f9 elle a fait partie de l&rsquo;\u00e9quipe de lancement du premier m\u00e9dicament orphelin approuv\u00e9 en Europe. Elle y a ensuite occup\u00e9 des fonctions \u00e0 responsabilit\u00e9s croissantes et dirig\u00e9 plusieurs \u00e9quipes strat\u00e9giques et op\u00e9rationnelles, aux niveaux local et mondial, dans diff\u00e9rents pays europ\u00e9ens et aux \u00c9tats-Unis.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><div class=\"team-member staff-team\"><div class=\"team-member-inner\"><div class=\"image-and-links\"><div class=\"team-member-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12.png\" class=\"wp-image-8555 avia-img-lazy-loading-8555 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"read-bio-and-social\"><button class=\"view-bio open-popup avia-button\" popup-target=\"#8554\">Biographie<\/button><div class=\"social-links\"><\/div><\/div><\/div><div class=\"team-member-content\"><div class=\"textblock\"><h4 class=\"open-popup\" popup-target=\"#8554\">Elsy Boglioli<\/h4><p class=\"job-title\"> Administratrice ind\u00e9pendante<\/p><\/div><\/div><\/div><div id=\"8554\" class=\"popup-content\"><div class=\"popup-bg\"><\/div><div class=\"popup-inner\"><div class=\"popup-aligner\"><div class=\"popup-dots\"><img decoding=\"async\" class=\"default\" src=\"\/wp-content\/uploads\/2026\/06\/Group-5895-3.png\" alt=\"decorative dots\" \/><img decoding=\"async\" class=\"hover\" src=\"\/wp-content\/uploads\/2026\/09\/Group-5895-1.png\" alt=\"decorative dots\" \/><\/div><div class=\"popup-close\"><span class=\"popup-close-inner\"><\/span><\/div><div class=\"popup-inner-content\"><div class=\"popup-left\"><div class=\"popup-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12.png\" class=\"wp-image-8555 avia-img-lazy-loading-8555 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-12-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"social-links\"><\/div><\/div><div class=\"popup-right\"><h2>Elsy Boglioli<\/h2><h4> Administratrice ind\u00e9pendante<\/h4>\n<p class=\"wp-block-paragraph\">Elsy Boglioli est administratrice de GenSight Biologics depuis 2020. <\/p>\n\n<p class=\"wp-block-paragraph\">Elle est fondatrice et Directrice G\u00e9n\u00e9rale de Bio-Up, cabinet de conseil en sant\u00e9 qui accompagne les entreprises dans leurs phases de forte croissance ou de transformation, principalement dans le domaine des th\u00e9rapies cellulaire et g\u00e9nique. Elle poss\u00e8de une expertise \u00e9tendue et un large r\u00e9seau dans les secteurs de la pharmacie et des technologies m\u00e9dicales. <\/p>\n\n<p class=\"wp-block-paragraph\">Avant de cr\u00e9er Bio-Up, Mme Boglioli a \u00e9t\u00e9 Vice-Pr\u00e9sidente ex\u00e9cutive et Directrice des op\u00e9rations de Cellectis, soci\u00e9t\u00e9 fran\u00e7aise de biotechnologie sp\u00e9cialis\u00e9e dans l&rsquo;\u00e9dition du g\u00e9nome et ses applications en oncologie. Chez Cellectis, elle a dirig\u00e9 plusieurs fonctions strat\u00e9giques et op\u00e9rationnelles, de la strat\u00e9gie au d\u00e9veloppement commercial, en passant par la gestion des programmes d&rsquo;essais cliniques et la fabrication, avec pour objectif de renforcer les capacit\u00e9s internes.  <\/p>\n\n<p class=\"wp-block-paragraph\">Avant Cellectis, Mme Boglioli a travaill\u00e9 12 ans au Boston Consulting Group (BCG), o\u00f9 elle a \u00e9t\u00e9 Partner et Managing Director au bureau de Paris et a dirig\u00e9 l&rsquo;activit\u00e9 biotechnologie du cabinet en Europe. Elle a collabor\u00e9 \u00e9troitement avec des soci\u00e9t\u00e9s de biotechnologie et de pharmacie sur des sujets tels que l&rsquo;optimisation du lancement de produits de sp\u00e9cialit\u00e9, les partenariats et les fusions-acquisitions.  <\/p>\n\n<p class=\"wp-block-paragraph\">Elsy Boglioli est dipl\u00f4m\u00e9e de l&rsquo;\u00c9cole polytechnique, \u00e0 Paris, et titulaire d&rsquo;un master en \u00e9conomie et gestion de l&rsquo;Universit\u00e9 Pompeu Fabra de Barcelone, en Espagne. Elle d\u00e9tient \u00e9galement un dipl\u00f4me en immuno-oncologie de l&rsquo;Institut Gustave Roussy, \u00e0 Paris. <\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><div class=\"team-member staff-team\"><div class=\"team-member-inner\"><div class=\"image-and-links\"><div class=\"team-member-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13.png\" class=\"wp-image-8557 avia-img-lazy-loading-8557 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"read-bio-and-social\"><button class=\"view-bio open-popup avia-button\" popup-target=\"#8556\">Biographie<\/button><div class=\"social-links\"><\/div><\/div><\/div><div class=\"team-member-content\"><div class=\"textblock\"><h4 class=\"open-popup\" popup-target=\"#8556\">Prof. Jos\u00e9-Alain Sahel, M.D., Ph.D.<\/h4><p class=\"job-title\">Administrateur<\/p><\/div><\/div><\/div><div id=\"8556\" class=\"popup-content\"><div class=\"popup-bg\"><\/div><div class=\"popup-inner\"><div class=\"popup-aligner\"><div class=\"popup-dots\"><img decoding=\"async\" class=\"default\" src=\"\/wp-content\/uploads\/2026\/06\/Group-5895-3.png\" alt=\"decorative dots\" \/><img decoding=\"async\" class=\"hover\" src=\"\/wp-content\/uploads\/2026\/09\/Group-5895-1.png\" alt=\"decorative dots\" \/><\/div><div class=\"popup-close\"><span class=\"popup-close-inner\"><\/span><\/div><div class=\"popup-inner-content\"><div class=\"popup-left\"><div class=\"popup-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13.png\" class=\"wp-image-8557 avia-img-lazy-loading-8557 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-13-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"social-links\"><\/div><\/div><div class=\"popup-right\"><h2>Prof. Jos\u00e9-Alain Sahel, M.D., Ph.D.<\/h2><h4>Administrateur<\/h4>\n<p class=\"wp-block-paragraph\">Le Pr Jos\u00e9-Alain Sahel est un ophtalmologiste et scientifique franco-am\u00e9ricain de renomm\u00e9e internationale, dont la carri\u00e8re acad\u00e9mique et hospitali\u00e8re exceptionnelle s&rsquo;est d\u00e9ploy\u00e9e en France, au Royaume-Uni et aux \u00c9tats-Unis.<\/p>\n\n<p class=\"wp-block-paragraph\">Dipl\u00f4m\u00e9 de la facult\u00e9 de m\u00e9decine de Paris (m\u00e9daill\u00e9 en 1980), il s&rsquo;est sp\u00e9cialis\u00e9 en ophtalmologie \u00e0 Strasbourg, \u00e0 Paris et \u00e0 l&rsquo;universit\u00e9 Harvard. De 2001 \u00e0 2021, il a dirig\u00e9 deux services d&rsquo;ophtalmologie, \u00e0 l&rsquo;H\u00f4pital national des Quinze-Vingts et \u00e0 la Fondation ophtalmologique Rothschild, tous deux \u00e0 Paris, et il a fond\u00e9 en 2008 l&rsquo;Institut de la Vision, devenu l&rsquo;un des plus grands centres de recherche int\u00e9gr\u00e9s d&rsquo;Europe sur les maladies de la vision.  <\/p>\n\n<p class=\"wp-block-paragraph\">Le Pr Sahel a \u00e9t\u00e9 professeur \u00e0 Sorbonne Universit\u00e9 et a occup\u00e9 la chaire Cumberlege de sciences biom\u00e9dicales \u00e0 l&rsquo;Institut d&rsquo;ophtalmologie de l&rsquo;University College London. Il est aujourd&rsquo;hui Distinguished Professor (professeur de rang exceptionnel) et directeur du d\u00e9partement d&rsquo;ophtalmologie de l&rsquo;universit\u00e9 de Pittsburgh, o\u00f9 il dirige l&rsquo;Institut de la vision de l&rsquo;UPMC. <\/p>\n\n<p class=\"wp-block-paragraph\">Ses travaux pionniers sur la compr\u00e9hension et le traitement des maladies r\u00e9tiniennes incurables ont ouvert des avanc\u00e9es majeures en th\u00e9rapie g\u00e9nique, optog\u00e9n\u00e9tique, r\u00e9tine artificielle et neuroprotection, dont plusieurs ont donn\u00e9 lieu \u00e0 de premiers essais chez l&rsquo;humain. Il est notamment le co-d\u00e9couvreur du facteur de viabilit\u00e9 des c\u00f4nes (RdCVF), qui ouvre la voie \u00e0 de nouvelles strat\u00e9gies pour pr\u00e9server la vision centrale dans la r\u00e9tinite pigmentaire et la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l&rsquo;\u00e2ge, et il a men\u00e9 les premi\u00e8res applications cliniques r\u00e9ussies de l&rsquo;optog\u00e9n\u00e9tique et d&rsquo;une proth\u00e8se r\u00e9tinienne sans fil. <\/p>\n\n<p class=\"wp-block-paragraph\">Le Pr Sahel est l&rsquo;auteur de plus de 800 publications scientifiques et l&rsquo;inventeur de nombreux brevets. Il a re\u00e7u de prestigieuses r\u00e9compenses et distinctions, parmi lesquelles son \u00e9lection \u00e0 plusieurs acad\u00e9mies, la L\u00e9gion d&rsquo;honneur, l&rsquo;Ordre national du M\u00e9rite, la m\u00e9daille de l&rsquo;Innovation du CNRS, le prix Wolf de m\u00e9decine 2024 et la m\u00e9daille Proctor de l&rsquo;ARVO 2026.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><div class=\"team-member staff-team\"><div class=\"team-member-inner\"><div class=\"image-and-links\"><div class=\"team-member-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14.png\" class=\"wp-image-8559 avia-img-lazy-loading-8559 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"read-bio-and-social\"><button class=\"view-bio open-popup avia-button\" popup-target=\"#8558\">Biographie<\/button><div class=\"social-links\"><\/div><\/div><\/div><div class=\"team-member-content\"><div class=\"textblock\"><h4 class=\"open-popup\" popup-target=\"#8558\">William Monteith<\/h4><p class=\"job-title\">Administrateur ind\u00e9pendant<\/p><\/div><\/div><\/div><div id=\"8558\" class=\"popup-content\"><div class=\"popup-bg\"><\/div><div class=\"popup-inner\"><div class=\"popup-aligner\"><div class=\"popup-dots\"><img decoding=\"async\" class=\"default\" src=\"\/wp-content\/uploads\/2026\/06\/Group-5895-3.png\" alt=\"decorative dots\" \/><img decoding=\"async\" class=\"hover\" src=\"\/wp-content\/uploads\/2026\/09\/Group-5895-1.png\" alt=\"decorative dots\" \/><\/div><div class=\"popup-close\"><span class=\"popup-close-inner\"><\/span><\/div><div class=\"popup-inner-content\"><div class=\"popup-left\"><div class=\"popup-image\"><img decoding=\"async\" loading=\"lazy\" width=\"413\" height=\"413\" src=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14.png\" class=\"wp-image-8559 avia-img-lazy-loading-8559 attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"\" srcset=\"https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14.png 413w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14-300x300.png 300w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14-80x80.png 80w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14-36x36.png 36w, https:\/\/www.gensight-biologics.com\/wp-content\/uploads\/2026\/06\/Rectangle-840-14-180x180.png 180w\" sizes=\"auto, (max-width: 413px) 100vw, 413px\" \/><\/div><div class=\"social-links\"><\/div><\/div><div class=\"popup-right\"><h2>William Monteith<\/h2><h4>Administrateur ind\u00e9pendant<\/h4>\n<p class=\"wp-block-paragraph\">William J. Monteith a rejoint le Conseil d&rsquo;administration en 2024. Il apporte plus de 40 ans d&rsquo;exp\u00e9rience dans la fabrication pharmaceutique, de petites comme de grandes mol\u00e9cules. Tout au long de sa carri\u00e8re, il a occup\u00e9 des postes \u00e0 responsabilit\u00e9s croissantes en op\u00e9rations, qualit\u00e9 et support technique, et a directement particip\u00e9 \u00e0 la recherche de sites, \u00e0 la conception et \u00e0 la construction de six installations pharmaceutiques et biotechnologiques.  <\/p>\n\n<p class=\"wp-block-paragraph\">Chez Wyeth et Sandoz, M. Monteith a supervis\u00e9 la mise en \u0153uvre r\u00e9ussie de mesures correctives faisant suite \u00e0 des actions r\u00e9glementaires. Il \u00e9tait directeur g\u00e9n\u00e9ral de Dendreon lors de l&rsquo;approbation et de la commercialisation de la premi\u00e8re m\u00e9decine personnalis\u00e9e \u00e0 base de cellules dendritiques, avant d&rsquo;en devenir Vice-Pr\u00e9sident ex\u00e9cutif, responsable de la cha\u00eene d&rsquo;approvisionnement de production et du lancement de Provenge\u00ae en Europe.  <\/p>\n\n<p class=\"wp-block-paragraph\">Apr\u00e8s la cession de Dendreon \u00e0 Valeant, M. Monteith a \u00e9t\u00e9 nomm\u00e9 Directeur des op\u00e9rations de Progenitor Cell Therapy, un CDMO ensuite rachet\u00e9 par Hitachi Chemical. Chez Hitachi, il a supervis\u00e9 l&rsquo;agrandissement du site d&rsquo;Allendale (New Jersey) ainsi que la construction d&rsquo;une usine de th\u00e9rapie cellulaire et g\u00e9nique \u00e0 Yokohama, au Japon. \u00c0 son d\u00e9part de Hitachi Chemical Advanced Therapies, il a rejoint Cellectis comme Vice-Pr\u00e9sident Fabrication pour l&rsquo;Am\u00e9rique du Nord, charg\u00e9 d&rsquo;y implanter un site de production de CAR-T ; il a finalement supervis\u00e9 l&rsquo;achat et l&rsquo;am\u00e9nagement d&rsquo;une usine \u00e0 Raleigh, en Caroline du Nord. Peu apr\u00e8s, il a \u00e9t\u00e9 nomm\u00e9 Vice-Pr\u00e9sident ex\u00e9cutif des op\u00e9rations mondiales de Cellectis, responsable des d\u00e9partements op\u00e9rationnels de Raleigh et de Paris.   <\/p>\n\n<p class=\"wp-block-paragraph\">\u00c0 son d\u00e9part de Cellectis, M. Monteith a \u00e9t\u00e9 nomm\u00e9 Directeur des op\u00e9rations de StrideBio, soci\u00e9t\u00e9 de recherche et d\u00e9veloppement sp\u00e9cialis\u00e9e dans les produits AAV contre les maladies rares, o\u00f9 il a pilot\u00e9 la constitution des d\u00e9partements op\u00e9rationnels et d&rsquo;une unit\u00e9 de fabrication clinique.  <\/p>\n\n<p class=\"wp-block-paragraph\">Depuis sa retraite, M. Monteith est Directeur de programme du North Carolina Life Sciences Biomanufacturing Forum, organisation professionnelle qui d\u00e9fend les entreprises des sciences de la vie implant\u00e9es dans l&rsquo;\u00c9tat. Il est \u00e9galement conseiller ex\u00e9cutif chez Kymanox, prestataire de services pour l&rsquo;industrie des sciences de la vie, et si\u00e8ge au comit\u00e9 consultatif de GXP Storage Solution. <\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n<\/div><\/section><\/div>\n<\/div><\/div><\/div><!-- close content main div --><\/div><\/div><div id='after_section_2'  class='main_color av_default_container_wrap container_wrap sidebar_right'  ><div class='container av-section-cont-open' ><div class='template-page content  av-content-small alpha units'><div class='post-entry post-entry-type-page post-entry-8776'><div class='entry-content-wrapper clearfix'>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":8767,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-8776","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Conseil d&#039;administration | GenSight Biologics<\/title>\n<meta name=\"description\" content=\"Rencontrez le conseil d&#039;administration international qui accompagne la strat\u00e9gie de GenSight Biologics, biotech sp\u00e9cialis\u00e9e en th\u00e9rapie g\u00e9nique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Conseil d&#039;administration | GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Rencontrez le conseil d&#039;administration international qui accompagne la strat\u00e9gie de GenSight Biologics, biotech sp\u00e9cialis\u00e9e en th\u00e9rapie g\u00e9nique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-29T16:12:48+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"20 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/societe\\\/conseil-dadministration\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/societe\\\/conseil-dadministration\\\/\",\"name\":\"Conseil d'administration | GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-09-23T02:21:50+00:00\",\"dateModified\":\"2026-10-29T16:12:48+00:00\",\"description\":\"Rencontrez le conseil d'administration international qui accompagne la strat\u00e9gie de GenSight Biologics, biotech sp\u00e9cialis\u00e9e en th\u00e9rapie g\u00e9nique.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/societe\\\/conseil-dadministration\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/societe\\\/conseil-dadministration\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/societe\\\/conseil-dadministration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Soci\u00e9t\u00e9\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/societe\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conseil d&rsquo;administration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Conseil d'administration | GenSight Biologics","description":"Rencontrez le conseil d'administration international qui accompagne la strat\u00e9gie de GenSight Biologics, biotech sp\u00e9cialis\u00e9e en th\u00e9rapie g\u00e9nique.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/","og_locale":"fr_FR","og_type":"article","og_title":"Conseil d'administration | GenSight Biologics","og_description":"Rencontrez le conseil d'administration international qui accompagne la strat\u00e9gie de GenSight Biologics, biotech sp\u00e9cialis\u00e9e en th\u00e9rapie g\u00e9nique.","og_url":"https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/","og_site_name":"GenSight Biologics","article_modified_time":"2026-10-29T16:12:48+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"20 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/","url":"https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/","name":"Conseil d'administration | GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2026-09-23T02:21:50+00:00","dateModified":"2026-10-29T16:12:48+00:00","description":"Rencontrez le conseil d'administration international qui accompagne la strat\u00e9gie de GenSight Biologics, biotech sp\u00e9cialis\u00e9e en th\u00e9rapie g\u00e9nique.","breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/societe\/conseil-dadministration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Soci\u00e9t\u00e9","item":"https:\/\/www.gensight-biologics.com\/fr\/societe\/"},{"@type":"ListItem","position":3,"name":"Conseil d&rsquo;administration"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/pages\/8776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=8776"}],"version-history":[{"count":7,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/pages\/8776\/revisions"}],"predecessor-version":[{"id":9909,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/pages\/8776\/revisions\/9909"}],"up":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/pages\/8767"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=8776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}